InMed Pharmaceuticals Inc. Common Shares - INM STOCK NEWS

InMed Pharmaceuticals (Nasdaq: INM) announced that President and CEO Eric A. Adams will present at the virtual 2021 BIO Digital conference from June 10-11 and June 14-18. The presentation will cover the company's latest advancements, including the IntegraSyn™ cannabinoid manufacturing system and the Phase 2 clinical development of INM-755, a cannabinol cream for epidermolysis bullosa. Attendees can access the presentation starting at 9 am ET on June 10. Additionally, Adams and CFO Bruce Colwill will hold meetings via the BIO One-on-One Partnering™ system from June 14.

InMed Pharmaceuticals (NASDAQ: INM) reported its financial results for 3Q21, ending March 31, 2021. The company achieved significant milestones in its INM-755 therapeutic program for Epidermolysis Bullosa, filing Clinical Trial Applications in several countries. InMed's IntegraSyn manufacturing process reached a commercially viable cannabinoid yield of 2g/L, supporting large-scale production plans. Despite a net loss of $3.1 million for the quarter, cash reserves increased to $9.5 million. The company delisted from the TSX while maintaining its Nasdaq listing.

InMed Pharmaceuticals Inc. (NASDAQ:INM) will report its financial results for Q3 FY2021 on May 13, 2021. This quarter ended on March 31, 2021. The Company is focused on the development of cannabinoid-based drug candidates, particularly cannabinol (CBN), aimed at addressing high unmet medical needs. A conference call and webcast will occur on the same day at 8:00 AM PT / 11:00 AM ET, with a replay available for 90 days. Full financials will be accessible on InMed's official website as well as SEDAR and SEC platforms.

On May 4, 2021, InMed Pharmaceuticals (Nasdaq: INM; TSX:IN) announced that Eric A. Adams, President and CEO, will present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11, 2021. The presentation is scheduled for 2:30-2:55 PM EDT and can be accessed virtually. Eric A. Adams and CFO Bruce Colwill will also engage in one-on-one meetings with institutional investors during the conference. InMed focuses on developing cannabinoid-based pharmaceutical candidates, particularly cannabinol (CBN), targeting unmet medical needs.

InMed Pharmaceuticals has filed Clinical Trial Applications (CTAs) for its Phase 2 trial of INM-755 cream to treat Epidermolysis Bullosa (EB) in Austria, Israel, and Serbia. Further submissions are planned in France, Germany, Greece, and Italy. The company expects to begin the study in 3Q 2021, aiming to enroll up to 20 patients at 10 clinical sites within 10-12 months. Preliminary efficacy will be evaluated over 28 days. Results are anticipated in the latter half of 2022, contingent on regulatory approvals.

InMed Pharmaceuticals Inc. announces the voluntary delisting of its common shares from the Toronto Stock Exchange (TSX) while maintaining its listing on the Nasdaq. This decision comes as trading volume on the TSX no longer justifies the costs associated with dual listing. InMed’s shares have primarily traded on Nasdaq, accounting for approximately 86% of trading volume since November 2020. The anticipated delisting from the TSX will occur around May 7, 2021, with Canadian shareholders able to trade their shares on Nasdaq through their brokers.

InMed Pharmaceuticals has achieved a cannabinoid yield of 2g/L via its IntegraSyn™ manufacturing approach, marking a significant milestone towards commercial viability. The company aims to scale up production for pharmaceutical-grade cannabinoids and optimize manufacturing costs. InMed plans to produce a one-kilogram batch in the second half of 2021. They are also preparing for Good Manufacturing Practice (GMP) certification. This achievement positions InMed for potential advancements in cannabinoid-based pharmaceutical drugs.

InMed Pharmaceuticals has announced participation in two investor conferences in March 2021. Eric A. Adams, President and CEO, will present at the H.C. Wainwright Global Life Sciences Conference from March 9-10, with an on-demand presentation available starting March 9 at 7 AM EST. Additionally, he will engage in a Fireside Chat at the 33rd Annual ROTH Conference on March 15 at 4:30 PM EST. InMed is focused on developing cannabinoid-based pharmaceutical candidates, specifically targeting unmet medical needs through cannabinol (CBN).

InMed Pharmaceuticals has completed a private placement, raising approximately US$4.0 million in net proceeds by selling 1,050,000 units at US$4.25 per unit. Each unit consists of one common share and 0.66 of a warrant with an exercise price of US$4.85.

The funds will be used for working capital purposes. InMed plans to file a registration statement with the SEC within 30 days for the common shares and warrants issued, although these securities have not been registered under the Securities Act.